It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are ...

Core Insights - Amgen reported strong Q3 2025 earnings, with adjusted earnings of $5.64 per share, surpassing the Zacks Consensus Estimate of $5.00, and total revenues of $9.6 billion, exceeding the estimate of $8.9 billion, reflecting a 12% year-over-year increase [2][3] Financial Performance - Total product revenues increased by 12% year-over-year to $9.17 billion, driven by a 14% rise in volume, although partially offset by a 4% decline in pricing [3] - Other revenues rose by 19.3% year-over-year to $420 million, primarily due to higher royalty income [3] - Adjusted operating margin decreased by 2.5 percentage points to 47.1%, with operating expenses increasing by 18% to $5.25 billion [22] Key Product Performance - Prolia revenues reached $1.14 billion, up 9% year-over-year, significantly exceeding the Zacks Consensus Estimate of $911 million [6] - Evenity sales grew by 36% year-over-year to $541 million, surpassing the Zacks Consensus Estimate of $519 million [7] - Repatha generated revenues of $794 million, a 40% increase year-over-year, beating the Zacks Consensus Estimate of $720 million [7] - Biosimilar portfolio sales surged by 52% year-over-year to $775 million [5] Guidance and Outlook - Amgen raised its 2025 revenue and earnings outlook, expecting total revenues between $35.8 billion and $36.6 billion, and adjusted earnings per share in the range of $20.60 to $21.40 [24] - Adjusted operating margin is anticipated to be around 45%, with R&D expenses expected to grow at a mid-20s percentage rate year-over-year [25] Pipeline Developments - Enrollment has been completed in two phase III studies for MariTide, with approximately 5,000 adults enrolled [27] - Ongoing enrollment in two other phase III studies for atherosclerotic cardiovascular disease and heart failure [28]

Core Insights - High-rolling investors are bullish on Amgen (NASDAQ:AMGN), indicating potential privileged information influencing their trading decisions [1] - The sentiment among major traders is predominantly bullish, with 75% of options trades being calls and only 0% bearish [2] - Significant price targets for Amgen have been identified, ranging from $290.0 to $400.0 over the last three months [3] Options Trading Activity - A total of 8 options trades were detected for Amgen, with a notable imbalance favoring calls over puts [1][2] - The total trade price for the identified options includes $422,130 for calls and $30,600 for a put [2] - Recent options trades include various strike prices, with significant trades such as a bullish call for $400.00 expiring on January 16, 2026, totaling $180.6K [8] Company Overview - Amgen is a leader in biotechnology, known for its therapeutics including Epogen, Neupogen, and Enbrel, among others [9] - The company has expanded its portfolio through acquisitions and recent drug launches, including treatments for cancer and rare diseases [9] - Amgen's current market position is supported by expert ratings, with an average target price of $314.67 from three analysts [11][12] Current Market Status - Amgen's stock is currently trading at $337.81, reflecting a 0.45% increase [14] - The stock's trading volume is reported at 163,220, with RSI readings suggesting it may be overbought [14] - Anticipated earnings release is scheduled in 82 days, which may impact future trading activity [14]

Core Viewpoint - Amgen is expected to report quarterly earnings of $5.25 per share, reflecting a 5.6% increase year-over-year, with revenues forecasted at $8.86 billion, also representing a 5.6% year-over-year increase [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been adjusted downward by 0.2%, indicating a reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock performance [3]. Revenue and Product Sales Estimates - The consensus estimate for 'Revenue- Product sales' is $8.49 billion, indicating a year-over-year change of +5.6% [5]. - Analysts project 'Product Sales- Neulasta- Total' to reach $92.14 million, reflecting a -12.3% change from the previous year [5]. - 'Product Sales- LUMAKRAS/LUMYKRAS- Total' is expected to be $91.20 million, showing a +7.3% year-over-year change [5]. - 'Product Sales- Otezla- Total' is estimated at $533.54 million, indicating a -1.9% change year-over-year [6]. - 'Product Sales- Neulasta- ROW' is projected at $23.31 million, reflecting a -22.3% change year-over-year [6]. - 'Product Sales- Neulasta- U.S.' is expected to be $66.88 million, indicating a -10.8% change from the prior year [6]. - 'Product Sales- Vectibix- ROW' is estimated at $135.60 million, showing a -1% change from the previous year [7]. - 'Product Sales- Vectibix- U.S.' is forecasted to reach $141.96 million, reflecting a +6.7% year-over-year change [7]. - 'Product Sales- Enbrel- U.S.' is expected to be $786.00 million, indicating a -12.9% change from the prior year [7]. - 'Product Sales- Enbrel- ROW' is projected at $7.01 million, reflecting a +0.1% change year-over-year [8]. - 'Product Sales- Aranesp- ROW' is estimated at $251.00 million, indicating a -2.3% change year-over-year [8]. - 'Product Sales- Aranesp- U.S.' is expected to be $80.25 million, reflecting a -11.8% change from the previous year [8]. Stock Performance - Over the past month, Amgen shares have recorded a return of +1.5%, compared to the Zacks S&P 500 composite's +2.7% change [9].

Company Overview - Amgen is one of the largest biotech companies globally, with a strong presence in oncology/hematology, cardiovascular disease, inflammation, bone health, and rare diseases markets [11] - The company has developed successful drugs such as Epogen and Neupogen, and launched next-generation products like Aranesp and Neulasta [11] - Amgen's acquisition of Immunex Corporation provided access to the blockbuster drug Enbrel, although older drugs are facing declining sales due to competition [11] Financial Performance - Amgen has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid position in the market [12] - The company is forecasted to achieve year-over-year earnings growth of 5.1% for the current fiscal year [12] - Recent upward revisions in earnings estimates by five analysts for fiscal 2025 have increased the Zacks Consensus Estimate by $0.09 to $20.85 per share [12] - Amgen has an average earnings surprise of +8.3%, reflecting its ability to exceed earnings expectations [12] Investment Potential - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, Amgen is recommended for investors looking for growth opportunities [13]

Company Overview - Amgen is one of the largest biotech companies globally, with a strong presence in oncology, cardiovascular disease, inflammation, bone health, and rare diseases markets [12] - The company has developed successful drugs such as Epogen and Neupogen, and launched next-generation products like Aranesp and Neulasta [12] - Amgen's acquisition of Immunex Corporation provided access to the blockbuster drug Enbrel, although older drugs are facing declining sales due to competition [12] Financial Performance - Amgen has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid position in the market [13] - The company is forecasted to achieve year-over-year earnings growth of 4.6% for the current fiscal year [13] - Recent upward revisions in earnings estimates by 10 analysts have increased the Zacks Consensus Estimate by $0.13 to $20.76 per share [13] - Amgen has an average earnings surprise of 8.3%, suggesting a positive trend in financial performance [13] Investment Potential - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, Amgen is recommended for investors' consideration [14]